Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mexiletine hydrochloride
Drug ID BADD_D01453
Description Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.
Indications and Usage For the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.
Marketing Status Prescription; Discontinued
ATC Code C01BB02
DrugBank ID DB00379
KEGG ID D00639
MeSH ID D008801
PubChem ID 21467
TTD Drug ID D0X0RI
NDC Product Code 42291-625; 46708-871; 62559-820; 0527-4107; 63629-1963; 63629-2145; 10135-731; 63629-1964; 17511-136; 0527-4109; 62559-822; 0093-8740; 51407-380; 63629-9179; 51407-381; 0093-8741; 51407-379; 0527-4108; 42291-626; 62756-956; 65977-0122; 10135-730; 63629-9180; 51927-2953; 50742-239; 42291-624; 62559-821; 0093-8739; 62756-955; 73435-007; 53296-0029; 10135-732; 63629-9181; 62756-957; 50742-241; 72166-007; 50742-240
Synonyms Mexiletine | Novo-Mexiletine | Novo Mexiletine | Mexiletine Hydrochloride | Mexitil | Mexitil PL | Mexityl | KO-1173 | KO 1173 | KO1173 | KOE-1173 | KOE 1173 | KOE1173 | Mexiletene
Chemical Information
Molecular Formula C11H18ClNO
CAS Registry Number 5370-01-4
SMILES CC1=C(C(=CC=C1)C)OCC(C)N.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
Sudden cardiac deathPotassium voltage-gated channel subfamily KQT member 1P51787T49526Not Available
Sudden cardiac deathSodium channel protein type 5 subunit alphaQ14524T39716Not Available
Sudden cardiac deathPotassium voltage-gated channel subfamily E member 1P15382Not AvailableNot Available
Sudden cardiac deathPotassium voltage-gated channel subfamily H member 2Q12809T20251Not Available
Toxicity to various agentsCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Seizure17.12.03.001--
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.003--Not Available
Stevens-Johnson syndrome23.03.01.007; 11.07.01.005; 12.03.01.014; 10.01.03.020--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Tremor17.01.06.002--
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.006--
Urinary hesitation20.02.02.009--Not Available
Urinary retention20.02.02.011--
Ventricular arrhythmia02.03.04.006--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Antinuclear antibody positive13.06.01.003--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Appetite disorder14.03.01.004; 19.09.01.002--Not Available
Laryngeal disorder22.04.01.001--Not Available
Mental disorder19.07.01.002--Not Available
Erectile dysfunction19.08.04.001; 21.03.01.007--
Blood disorder01.05.01.004--Not Available
Abnormal sleep-related event19.02.03.009; 17.15.02.007--Not Available
Psychotic disorder19.03.01.002--
Salivary gland disorder07.06.02.001--Not Available
Pharyngeal disorder22.04.05.007--Not Available
Atrioventricular conduction time shortened02.03.01.014--Not Available
The 3th Page    First    Pre   3    Total 3 Pages